Innovation Pharmaceuticals Inc (IPIX)

[djs7]

Maybe - just opinion - they expanded cohort 11 at the 750 mark if they are seeing another 1 or 2 tumor types that are starting to respond in a manner like the ovarian cancer tumors given ORPHAN DRUG designation. If so, probably make sense to check this or these tumor type(s) at 750 with expanded patients, before going to an increased dosage where a risk of a DLT might (who knows when) occur.